EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

Opinion
Video

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content